Hall Steven Edward 4
4 · Forma Therapeutics Holdings, Inc. · Filed Nov 25, 2020
Insider Transaction Report
Form 4
Hall Steven Edward
Director
Transactions
- Conversion
Common Stock
2020-06-23+2,106,828→ 2,404,069 total(indirect: See footnote) - Conversion
Series C Preferred Stock
2020-06-23−3,178,630→ 0 total(indirect: See footnote)→ Common Stock (743,105 underlying) - Conversion
Series B Preferred Stock
2020-06-23−5,833,333→ 0 total(indirect: See footnote)→ Common Stock (1,363,723 underlying)
Footnotes (4)
- [F1]This Form 4 is being filed late due to an inadvertent administrative oversight and not any error of the reporting person.
- [F2]Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering on June 23, 2020.
- [F3]All series of preferred stock automatically converted into the Issuer's common stock on a one-for-4.2775 basis upon the closing of the Issuer's initial public offering on June 23, 2020 and had no expiration date.
- [F4]These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.